1)Himi T, et al:A novel concept of Mikulicz's disease as IgG4related disease. Auris Nasus Larynx 39:9-17, 2011
2)氷見徹夫・他:頭頸部領域のIgG4関連疾患.耳鼻臨床106:671-682,2013
3)Hamano H, et al:High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344:732-738, 2001
4)Yamamoto M, et al:Elevated IgG4 concentration in serum of patients with Mikulicz's disease. Scand J Rheumatol 33:432-433, 2004
5)Umehara H, et al:A novel clinical entity, IgG4-related disease(IgG4-RD), 2011. Mod Rheumatol 22:21-30, 2012
6)Stone JH, et al:IgG4-related disease. N Engl J Med 366:539-551, 2012
7)Umehara H, et al:Comprehensive diagnostic criteria for IgG4-related disease(IgG4-RD), 2011. Mod Rheumatol 22:21-30, 2012
8)高野賢一・他:特殊疾患診療NAVI IgG4関連疾患.耳喉頭頸84:345-350,2012
9)Deshpande V, et al:Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181-1192, 2012
10)Takano K, et al:Evaluation of submandibular versus labial salivary gland fibrosis in IgG4-related disease. Mod Rheumatol 2013(in press)
11)Seki N, et al:Spontaneous regression of lung lesions after excision of the submandibular gland in a patient with chronic sclerosing sialadenitis. Auris Nasus Larynx 39:212-215, 2012
12)Shimizu Y, et al:Necessity of early invention for IgG4-related disease-delayed treatment induces fibrosis progression. Rheumatology(Oxford)52:679-683, 2013
13)高橋裕樹・他:IgG4関連疾患.GUIDELINE 膠原病・リウマチ―治療ガイドラインをどう読むか―改訂第2版,小池隆夫・他(編).診断と治療社,東京,2010,pp43-49
14)Yamamoto M, et al:Beneficial effects of steroid therapy for Mikulicz's disease. Rheumatology(Oxford)44:1322-1323, 2005
15)Khosroshahi A, et al:Rituximab for the treatment of IgG4-related disease:lessons from 10 consecutive patients. Medicine(Baltimore)91:57-66, 2012
16)Khosroshahi A, et al:Rituximab therapy leads rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755-1762, 2012